Navigation Links
VersaPulse® 20 Watt

ProductsVersaPulse® 20 Watt
Company Lumenis Inc.
Item VersaPulse® 20 Watt
Features 
  • Highest power holmium laserup to 100 watts with 2 joules at 50 hertzprovides the smoothest cutting, faster, more efficient tissue effect, and reduced OR time
  • Upgrade capability for current and future applications
  • The only combination holmium/Nd:YAG laser system that provides multiple tissue effects through one delivery device
  • Compact size simplifies transportation and set-up
  • Solid state design with thirty-second warm-up for immediate use and problem-free maintenance
  • Over twenty fiber delivery systems compatible with multiple endoscopes
    • Description The VersaPulse® PowerSuite™ holmium laser combines excellent cutting, ablation and coagulation properties for precise, virtually bloodless procedures. It is also extremely effective in fragmenting urinary and gall bladder stones of all compositions, making it an ideal multipurpose surgical tool. Because its laser light is transmitted through flexible fibers, it is especially suited for minimally invasive endoscopic and laparoscopic procedures. The VersaPulse PowerSuite system comes in a variety of low- to high-power holmium models plus a combination holmium and neodymium:YAG (Nd:YAG) configuration. Lumenis™ is the pioneer in laser and light-based technology. Since introducing the first medical laser in 1970, over 60,000 systems have been used by nearly every medical specialty. Since introducing the first holmium laser in 1991, Lumenis has helped to expand the medical applications of this relatively new multipurpose laser. Today, holmium technology has been proven in thousands of procedures, securing the holmium laser its place as a well-respected minimally invasive treatment modality and the VersaPulse PowerSuite as the system of choice. VersaPulse PowerSuite lasers are used for ablation, excision, incision, vaporization and immediate hemostasis of soft tissues through endoscopic, laparoscopic and open access for a wide variety of surgical applications and procedures.
    Info Lumenis Inc.
    Customer Service: 877-lumenis
    Web site: http://www.lumenis.com

    Related medicine products :

    1. VersaPulse® 60 Watt
    2. VersaPulse® 100 Watt
    3. VersaPulse® 80/100 Watt
    ...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
    ...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
    ...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
    The Auto Suture™ ExtraHand™ balloon retractor is designed to be used during open surgery, gasless endoscopy, as well as endoscopy with gas insufflation.
    Medicine Products:
    (Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
    (Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
    (Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
    (Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
    Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
    ... first full-fledged Trauma center in India, Jai Pr...as conceived 22 years before, in 1984, is now read... All India Institute of Medical Sciences - JPNATC ...n-storey hospital with 200 beds, including 16 ICU ...
    ...y conducted a new study about alcoholism and publi...sm: Clinical & Experimental Research.// The study...ople initially fall asleep, but leads to poor-qual... night. · Escalated consumption of alcohol to aid...
    ...t rice (RYR) is known to contain several ingredien...tatin, and several trials have confirmed// its pos...onducted to assess the effectiveness and safety of...ipid levels in people with primary hyperlipidemia....
    ... study, using mice and heart muscle cells from rab...G?ttingen, Germany, have provided// a potential mo...beats known as ventricular tachyarrhythmias (VTs) ...iated with heart failure. Individuals who inherit...
    Other Medicine News:Health News:Alcohol Dependence For Sleep Perceptions May Result In Alcoholism 2Health News:Alcohol Dependence For Sleep Perceptions May Result In Alcoholism 3
    (Date:9/3/2008)...gium and GENEVA, Sept. 3 /- Artelis S...n CHO based monoclonal antibody,production with th...rams,per liter. This record level was accomplished...1) a high-performance stable Selexis CHO,productio...scientists at,Selexis SA using their proprietary S...
    (Date:9/3/2008)...howed that Multaq(R) (dronedarone) decreased the r...lation or atrial flutter already adeq...ATER, N.J., Sept. 3 /- The ...e ATHENA study were presented today at,the clinica...Cardiology,congress 2008, in Munich, Germany. Prev...
    (Date:9/3/2008)...es Operations, Updates Zingo Launch Progress and A... Conference Call Today at 11:30 a...swire-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV )...,operations to focus on commercial and late-stage ...o a specialty pharmaceutical pain management,compa...
    (Date:9/3/2008)... Evaluated in Repeat-Dosing Study in Subjects with...Call/ -- Sangamo,BioSciences, Inc. (Nasdaq: SGMO ...nical trial (SB-509-801) to evaluate its drug, SB-...tive motor-neuron disease for which there,are limi...g, SB-509, is an injectable formulation of a plasm...
    Breaking Medicine Technology:Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5How schizophrenia develops 3A Major clues discovered 841 1How schizophrenia develops 3A Major clues discovered 841 2The Childrens Institute Launches The Campaign for an Amazing Future 3862 1The Childrens Institute Launches The Campaign for an Amazing Future 3862 2The Childrens Institute Launches The Campaign for an Amazing Future 3862 3Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3858 1Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3858 2Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3858 3Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3858 4Ohio Delegation Members Urge Colleagues to Vote for Override of SCHIP Veto 3854 1Ohio Delegation Members Urge Colleagues to Vote for Override of SCHIP Veto 3854 2
    ...wswire/ -- Portola,Pharmaceuticals, Inc. announced...54021, an oral Factor Xa inhibitor, today at the X...osis and Haemostasis,(ISTH) in Geneva, Switzerland... effective, and well tolerated for the,prevention ...undergoing total knee replacement (TKR) surgery. P...
    ...or for U.S. Trial -, MISSISSAUGA, ON, July 11, 200...n oncology company that identifies, develops,and c... worldwide,today announced results of secondary e...ebo-controlled, multi-center Phase IIb,trial (DLXL...,inhaled-delivery composition of free and liposome...
    Other Medicine Technology:Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 3Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 4YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 2YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 3YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 4YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 5